Stock IKT INHIBIKASE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Delayed Nasdaq
Other stock markets
 18:31:38 17/05/2024 BST 		5-day change 1st Jan Change
1.743 USD -0.97% Intraday chart for Inhibikase Therapeutics, Inc. +33.05% +37.24%
05-16 Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024
05-09 Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders
Inhibikase Therapeutics Announces Preliminary Outcomes of Its Pre-Nda Meeting with the Fda on the Pathway for Approval for Ikt-001Pro in Blood and Gastrointestinal Cancers
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
Inhibikase Therapeutics, Inc. Provides Update on Development Programs
Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson?s Disease and Provides Update on Ongoing Enrollment
Sector Update: Health Care Stocks Advancing Late Afternoon
Sector Update: Health Care Stocks Lower Wednesday Afternoon
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Potential Multiple System Atrophy Treatment
Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib
Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Top Premarket Gainers
Inhibikase Therapeutics to Implement 1-for-6 Reverse Stock Split
Inhibikase Therapeutics, Inc. Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study
Inhibikase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IKT Stock
  4. News Inhibikase Therapeutics, Inc.
  5. Other languages